Insider · CIK 0001709024
Samuel Bates Martin
Files at CLDX (Celldex Therapeutics, Inc.). First filing -, latest -.
Samuel Bates Martin files SEC Form 4 as CFO at CLDX (Celldex Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Samuel Bates Martin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +93,000 | $0.00 | $0 | 93,000 | Jun 29, 2026 |
| Jan 2, 2026 | CLDX Celldex Therapeutics, Inc. | MOption exercise Common Stock | +4,817 | $10.38 | $50k | 32,942 | Jan 6, 2026 |
| Jan 2, 2026 | CLDX Celldex Therapeutics, Inc. | MOption exercise Incentive Stock Option (Right to Buy)derivative | -4,817 | $0.00 | $0 | 58,815 | Jan 6, 2026 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 9, 2025 |
Questions about Samuel Bates Martin
Answered from the filings on this page, as of the latest one.
Is Samuel Bates Martin buying or selling?
Samuel Bates Martin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Samuel Bates Martin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Samuel Bates Martin has 0.
Where does Samuel Bates Martin file Form 4?
Samuel Bates Martin has filed Form 4 at CLDX (Celldex Therapeutics, Inc.) as SVP AND CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.